Skip to main content

William W. O'Neill, MD

12/15/2019
Hemodynamic support is increasingly utilized to avoid hemodynamic collapse during high-risk CTO-PCI. We retrospectively evaluated procedural and clinical outcomes in consecutive patients undergoing Tandem Heart assisted CTO-PCI at our...
Hemodynamic support is increasingly utilized to avoid hemodynamic collapse during high-risk CTO-PCI. We retrospectively evaluated procedural and clinical outcomes in consecutive patients undergoing Tandem Heart assisted CTO-PCI at our...
Hemodynamic support is...
12/15/2019
Journal of Invasive Cardiology
Feature
06/19/2008
Greg Braden: Let’s discuss the issue of MI patients who live in communities where there is quick access to catheterization laboratories, versus those in remote communities who don’t have easy access to cath labs. We live in a modestly rural...
Greg Braden: Let’s discuss the issue of MI patients who live in communities where there is quick access to catheterization laboratories, versus those in remote communities who don’t have easy access to cath labs. We live in a modestly rural...
Greg Braden: Let’s discuss the...
06/19/2008
Cath Lab Digest
New Devices
07/08/2014
Transcatheter aortic valve replacement (TAVR) can be complicated by significant paravalvular leak (PVL). The aim of this study was to assess the utility of a proprietary software package, HeartNavigator (Philips), in selecting TAVR prosthesis...
Transcatheter aortic valve replacement (TAVR) can be complicated by significant paravalvular leak (PVL). The aim of this study was to assess the utility of a proprietary software package, HeartNavigator (Philips), in selecting TAVR prosthesis...
Transcatheter aortic valve...
07/08/2014
Journal of Invasive Cardiology
Feature
06/19/2008
When did you first start using the Cribier-Edwards percutaneous aortic heart valve? We received FDA approval in August 2003 for a one-time compassionate use. Dr. Alain Cribier, who did the first human clinical implants with the valve, had...
When did you first start using the Cribier-Edwards percutaneous aortic heart valve? We received FDA approval in August 2003 for a one-time compassionate use. Dr. Alain Cribier, who did the first human clinical implants with the valve, had...
When did you first start using...
06/19/2008
Cath Lab Digest
Qintar Figure 1
Video
09/01/2021
Angiographic series demonstrating the diagnosis and treatment of a large thrombus in the aortic arch (with a large mobile segment) in close proximity to the left subclavian artery origin.
Angiographic series demonstrating the diagnosis and treatment of a large thrombus in the aortic arch (with a large mobile segment) in close proximity to the left subclavian artery origin.
Angiographic series...
09/01/2021
Journal of Invasive Cardiology
Feature
08/01/2008
May 14, 2002 William O’Neill: There is a question for Dean Kereiakes. How will decreasing or eliminating restenosis impact surgical volume — obviously a major concern for surgeons and hospitals because coronary bypass surgery is a very...
May 14, 2002 William O’Neill: There is a question for Dean Kereiakes. How will decreasing or eliminating restenosis impact surgical volume — obviously a major concern for surgeons and hospitals because coronary bypass surgery is a very...
May 14, 2002 William O’Neill:...
08/01/2008
Journal of Invasive Cardiology
Version12
Video
03/14/2022
IAGS faculty members Srihari S. Naidu, MD, and William O’Neill, MD, discusses the recent NCSI study in JIC (Gorgis, et al) regarding cardiogenic shock patients and how so few are receiving adequate antiplatelet therapy.
IAGS faculty members Srihari S. Naidu, MD, and William O’Neill, MD, discusses the recent NCSI study in JIC (Gorgis, et al) regarding cardiogenic shock patients and how so few are receiving adequate antiplatelet therapy.
IAGS faculty members Srihari S....
03/14/2022
Journal of Invasive Cardiology
Feature
08/01/2008
May 15, 2002 Scott McMahon: Our first question is as follows: Do drug-eluting stents eliminate the need for IIb/IIIa platelet inhibitors and their associated costs which are reimbursed in DRG 516? William O’Neill: Dean, could you comment on...
May 15, 2002 Scott McMahon: Our first question is as follows: Do drug-eluting stents eliminate the need for IIb/IIIa platelet inhibitors and their associated costs which are reimbursed in DRG 516? William O’Neill: Dean, could you comment on...
May 15, 2002 Scott McMahon: Our...
08/01/2008
Journal of Invasive Cardiology
Original Contribution
02/15/2016
An investigation on whether the use of hemodynamic support during PCI can mitigate the adverse prognostic importance of surgical ineligibility. 
An investigation on whether the use of hemodynamic support during PCI can mitigate the adverse prognostic importance of surgical ineligibility. 
An investigation on whether the...
02/15/2016
Journal of Invasive Cardiology
Feature
08/01/2008
May 16, 2002 Scott McMahon: The first question this evening is as follows: What is your estimate of the aggregate increase or decrease in PCI procedures at one, two and five years following the introduction of drug-eluting stents? William...
May 16, 2002 Scott McMahon: The first question this evening is as follows: What is your estimate of the aggregate increase or decrease in PCI procedures at one, two and five years following the introduction of drug-eluting stents? William...
May 16, 2002 Scott McMahon: The...
08/01/2008
Journal of Invasive Cardiology